Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4(+)CD25(+) Regulatory T-cells of Type 1 Diabetic Subjects

Overview

Journal Diabetes

Specialty Endocrinology

Date 2009 Oct 31

PMID 19875613

Citations 148

Authors

S Alice Long

Karen Cerosaletti

Paul L Bollyky

Megan Tatum

Heather Shilling

Sheng Zhang

Zhong-Yin Zhang

Catherine Pihoker

Srinath Sanda

Carla Greenbaum

Jane H Buckner

Affiliations

Soon will be listed here.

Abstract

Objective: In humans, multiple genes in the interleukin (IL)-2/IL-2 receptor (IL-2R) pathway are associated with type 1 diabetes. However, no link between IL-2 responsiveness and CD4(+)CD25(+)FOXP3(+) regulatory T-cells (Tregs) has been demonstrated in type 1 diabetic subjects despite the role of these IL-2-dependent cells in controlling autoimmunity. Here, we address whether altered IL-2 responsiveness impacts persistence of FOXP3 expression in Tregs of type 1 diabetic subjects.

Research Design And Methods: Persistence of Tregs was assessed by culturing sorted CD4(+)CD25(hi) natural Tregs with IL-2 and measuring FOXP3 expression over time by flow cytometry for control and type 1 diabetic populations. The effects of IL-2 on FOXP3 induction were assessed 48 h after activation of CD4(+)CD25(-) T-cells with anti-CD3 antibody. Cytokine receptor expression and signaling upon exposure to IL-2, IL-7, and IL-15 were determined by flow cytometry and Western blot analysis.

Results: Maintenance of FOXP3 expression in CD4(+)CD25(+) Tregs of type 1 diabetic subjects was diminished in the presence of IL-2, but not IL-7. Impaired responsiveness was not linked to altered expression of the IL-2R complex. Instead, IL-2R signaling was reduced in Tregs and total CD4(+) T-cells of type 1 diabetic subjects. In some individuals, decreased signal transducer and activator of transcription 5 phosphorylation correlated with significantly higher expression of protein tyrosine phosphatase N2, a negative regulator of IL-2R signaling.

Conclusions: Aberrant IL-2R signaling in CD4(+) T-cells of type 1 diabetic subjects contributes to decreased persistence of FOXP3 expression that may impact establishment of tolerance. These findings suggest novel targets for treatment of type 1 diabetes within the IL-2R pathway and suggest that an altered IL-2R signaling signature may be a biomarker for type 1 diabetes.

Citing Articles

Cellular therapies in rheumatic and musculoskeletal diseases.

Franco-Fuquen P, Figueroa-Aguirre J, Martinez D, Moreno-Cortes E, Garcia-Robledo J, Vargas-Cely F J Transl Autoimmun. 2025; 10:100264.

PMID: 39931050 PMC: 11808717. DOI: 10.1016/j.jtauto.2024.100264.

Importance of Studying Non-Coding RNA in Children and Adolescents with Type 1 Diabetes.

Cabiati M, Federico G, Del Ry S Biomedicines. 2024; 12(9).

PMID: 39335501 PMC: 11429055. DOI: 10.3390/biomedicines12091988.

Cell-cell communication: new insights and clinical implications.

Su J, Song Y, Zhu Z, Huang X, Fan J, Qiao J Signal Transduct Target Ther. 2024; 9(1):196.

PMID: 39107318 PMC: 11382761. DOI: 10.1038/s41392-024-01888-z.

GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.

Uenishi G, Repic M, Yam J, Landuyt A, Saikumar-Lakshmi P, Guo T JCI Insight. 2024; 9(6).

PMID: 38516892 PMC: 11063937. DOI: 10.1172/jci.insight.171844.

Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes.

Tuomela K, Levings M Diabetologia. 2024; 67(4):611-622.

PMID: 38236408 DOI: 10.1007/s00125-023-06076-2.

References

Simoncic P, Lee-Loy A, Barber D, Tremblay M, McGlade C . The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr Biol. 2002; 12(6):446-53. DOI: 10.1016/s0960-9822(02)00697-8. View

Krutzik P, Hale M, Nolan G . Characterization of the murine immunological signaling network with phosphospecific flow cytometry. J Immunol. 2005; 175(4):2366-73. DOI: 10.4049/jimmunol.175.4.2366. View

Lowe C, Cooper J, Brusko T, Walker N, Smyth D, Bailey R . Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet. 2007; 39(9):1074-82. DOI: 10.1038/ng2102. View

Zheng S, Wang J, Wang P, Gray J, Horwitz D . IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol. 2007; 178(4):2018-27. DOI: 10.4049/jimmunol.178.4.2018. View

Willerford D, Chen J, Ferry J, Davidson L, Ma A, Alt F . Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 1995; 3(4):521-30. DOI: 10.1016/1074-7613(95)90180-9. View

Knoechel B, Lohr J, Kahn E, Bluestone J, Abbas A . Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005; 202(10):1375-86. PMC: 2212975. DOI: 10.1084/jem.20050855. View

Yu A, Malek T . Selective availability of IL-2 is a major determinant controlling the production of CD4+CD25+Foxp3+ T regulatory cells. J Immunol. 2006; 177(8):5115-21. DOI: 10.4049/jimmunol.177.8.5115. View

Long S, Buckner J . Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells. J Autoimmun. 2008; 30(4):293-302. PMC: 2431984. DOI: 10.1016/j.jaut.2007.12.012. View

Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A . Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30(6):899-911. DOI: 10.1016/j.immuni.2009.03.019. View

10.

Hoffmann P, Eder R, Boeld T, Doser K, Piseshka B, Andreesen R . Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood. 2006; 108(13):4260-7. DOI: 10.1182/blood-2006-06-027409. View

11.

Aoki C, Borchers A, Ridgway W, Keen C, Ansari A, Gershwin M . NOD mice and autoimmunity. Autoimmun Rev. 2005; 4(6):373-9. DOI: 10.1016/j.autrev.2005.02.002. View

12.

Malek T . The biology of interleukin-2. Annu Rev Immunol. 2007; 26:453-79. DOI: 10.1146/annurev.immunol.26.021607.090357. View

13.

Doody K, Bourdeau A, Tremblay M . T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease. Immunol Rev. 2009; 228(1):325-41. DOI: 10.1111/j.1600-065X.2008.00743.x. View

14.

Zorn E, Nelson E, Mohseni M, Porcheray F, Kim H, Litsa D . IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006; 108(5):1571-9. PMC: 1895505. DOI: 10.1182/blood-2006-02-004747. View

15.

Brusko T, Wasserfall C, Clare-Salzler M, Schatz D, Atkinson M . Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes. 2005; 54(5):1407-14. DOI: 10.2337/diabetes.54.5.1407. View

16.

Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner J . The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol. 2008; 181(10):7350-5. PMC: 2597079. DOI: 10.4049/jimmunol.181.10.7350. View

17.

Burchill M, Yang J, Vang K, Moon J, Chu H, Lio C . Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity. 2008; 28(1):112-21. PMC: 2430111. DOI: 10.1016/j.immuni.2007.11.022. View

18.

Sakaguchi S, Powrie F . Emerging challenges in regulatory T cell function and biology. Science. 2007; 317(5838):627-9. DOI: 10.1126/science.1142331. View

19.

Hakonarson H, Qu H, Bradfield J, Marchand L, Kim C, Glessner J . A novel susceptibility locus for type 1 diabetes on Chr12q13 identified by a genome-wide association study. Diabetes. 2008; 57(4):1143-6. DOI: 10.2337/db07-1305. View

20.

Strieder T, Drexhage H, Lam-Tse W, Prummel M, Tijssen J, Wiersinga W . A reduced IL2R (CD25) expression level in first and second degree female relatives of autoimmune thyroid disease patients. A sign of a poor capability to preserve tolerance?. Autoimmunity. 2006; 39(2):93-8. DOI: 10.1080/08916930500508092. View